Gilead Licenses Three Masked T Cell Engager Programs

Company Vir Biotechnology; Gilead Sciences Event Type Collaboration and Licensing Deal (with equity investment) Modality Protease-masked (PRO-XTEN dual-masked) T-cell engagers; AI-enabled protein engineering (dAIsY) Asset Three preclinical masked T-cell engager programs (undisclosed) Target Undisclosed solid-tumor antigens Disease Area Solid tumors Summary Vir Biotechnology and Gilead…